Abstract:Objective To investigate clinical effect of Gastrodin combined with Oxiracetam in the treatment of cognitive impairment after ischemic stroke in the elderly. Methods One hundred and two elderly patients with cognitive impairment after ischemic stroke who were admitted to the First People′s Hospital of Yunnan Province from January 2016 to December 2018 were selected, they were divided into control group (n = 51, Oxiracetam treatment) and study group (n = 51, Gastrodin combined with Oxiracetam treatment) according to the random number table method, two groups were treated for 1 month. Clinical efficacy, adverse reactions, Montreal cognitive assessment scale (MoCA) score, activities of daily living (ADL) score and serum levels of neuron-specific enolase (NSE), homocysteine (Hcy) and high-sensitivity C-reactive protein (hs-CRP) were compared between two groups. Results The total clinical effective rate of study group was higher than that of control group (P < 0.05). After treatment, the scores of MoCA and ADL in two groups were higher than those before treatment, and the scores in study group were higher than those in control group (P < 0.05). After treatment, the levels of NSE, Hcy and hs CRP in two groups were lower than those before treatment, and the level in study group was lower than that in control group (P < 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P > 0.05). Conclusion Gastrodin combined with Oxiracetam can effectively improve cognitive impairment in elderly patients with ischemic stroke. The safety of the drug is good and the effect is exact. The specific mechanism may be related to the down-regulation of NSE, Hcy, hs-CRP and other factors.
梁蔚蔚 刘华 李晓波. 天麻素联合奥拉西坦治疗老年缺血性脑卒中后认知功能障碍的临床研究[J]. 中国医药导报, 2020, 17(14): 78-81.
LIANG Weiwei LIU Hua LI Xiaobo. Clinical study of Gastrodin combined with Oxiracetam in the treatment of cognitive impairment in elderly patients with ischemic stroke. 中国医药导报, 2020, 17(14): 78-81.